Bristol Stool Scale and Modern Digestive Health Assessment

There is a profound gap between what we can see when we look at stool and what we can measure when we analyze it at the molecular level. That gap is one of the more consequential blind spots in digestive health assessment. The Bristol Stool Scale, for all its elegant simplicity and clinical ubiquity, captures a single physical variable while the biochemistry underneath goes unrecorded.

In 1997, Lewis and Heaton published the foundational description of the Bristol Stool Scale in the Scandinavian Journal of Gastroenterology, and it rapidly became the standard for clinical stool assessment. It deserved that status. For the first time clinicians had a validated, reproducible visual taxonomy for something they had been describing in vague terms for centuries: Type 1 (hard lumps), Type 2 (lumpy), Type 3 (sausage-shaped but cracked), Type 4 (smooth sausage), Type 5 (soft blobs), Type 6 (fluffy pieces) and Type 7 (entirely liquid). Simple, useful, and profoundly limited.

This article looks at how the scale's genuine clinical value can be combined with modern microbiome testing and VOC analysis to build a more complete picture of digestive health.

The Bristol Stool Scale: A Clinical Advance With Real Boundaries

What the Scale Gets Right

Before 1997, stool descriptions ranged from irregular to mushy, terminology with almost no precision. Lewis and Heaton applied systematic taxonomy to a biological variable that had been described in nearly every language with nearly no consistency.

The scale also correlates with something measurable, and the size of that correlation is known. In the original study, 66 volunteers had whole-gut transit time measured with radio-opaque markers while keeping a diary of stool form and frequency. Baseline transit time correlated with defecation frequency at r = 0.35 (p = 0.005) and with stool output at r = -0.41 (p = 0.001), but correlated best with stool form at r = -0.54 (p < 0.001). When transit was deliberately altered with senna and loperamide, the change in transit time again tracked change in stool form most closely, at r = -0.65 (p < 0.001) (Lewis and Heaton, 1997).

Those numbers are worth sitting with. A correlation of -0.54 is a real relationship and it is also far from determinism. Stool form explains part of the variance in transit time, not most of it. A later multicentre study by Saad and colleagues in constipated individuals and healthy controls reached the same conclusion, finding that stool form and frequency correlate with whole-gut and colonic transit but are not adequate surrogates for measured transit (American Journal of Gastroenterology, 2010).

Reliability has also been formally assessed. Blake and colleagues had 169 healthy volunteers classify their own stool alongside measured stool water content, compared results with 19 patients with diarrhoea-predominant irritable bowel syndrome, and had 86 volunteers classify 26 standardized stool models. They reported substantial validity and reliability overall, with the notable qualification that accuracy degraded precisely at the clinically important decision points between Types 2 and 3 and between Types 5 and 6 (Alimentary Pharmacology & Therapeutics, 2016).

Study	Design	Population	Key result
Lewis and Heaton, 1997	Radio-opaque marker transit, diary, senna and loperamide challenge	66 volunteers	Stool form vs transit r = -0.54; change in form vs change in transit r = -0.65
Saad et al., 2010	Multicentre transit measurement	Constipated individuals and healthy controls	Form and frequency correlate with transit but are not adequate surrogates
Blake et al., 2016	Self-classification vs stool water content; model classification	169 healthy adults, 19 IBS-D patients, 86 model raters	Substantial validity and reliability; accuracy falls at Types 2/3 and 5/6 boundaries
Vandeputte et al., 2016	16S profiling against stool consistency	53 healthy women	Species richness vs consistency r = -0.45 (p = 0.0007); enterotype and growth rate both associated
Asnicar et al., 2021	Blue dye transit marker plus metagenomics	863 PREDICT 1 participants	Measured transit time associated with the microbiome more strongly than stool consistency or frequency

Where Visual Assessment Reaches Its Limits

The scale tells us about one variable, consistency, which primarily reflects transit time and water content. That is not nothing, but it is not much. Consider what it does not tell us.

First, it cannot distinguish between different mechanisms producing identical appearances. A Type 5 stool could result from a fermentation pattern that is genuinely health-promoting, or from a dysbiotic state. Visually identical. Mechanistically distinct. Clinically important.

Second, it relies on subjective visual assessment, and Blake and colleagues showed exactly where that breaks down: at the boundaries that matter for clinical decisions.

Third, the scale provides no temporal resolution. Today's stool describes today's transit and water dynamics. It says nothing about the effect of a dietary change started last week.

Fourth, it captures no metabolomic information at all. Garner and colleagues identified 297 distinct volatile compounds in human fecal headspace, 44 of which were present in 80 percent of subjects (FASEB Journal, 2007). High concentrations of butyrate-associated metabolites indicate robust saccharolytic fermentation. Branched-chain fatty acids indicate protein fermentation. The Bristol Stool Scale reports none of this.

Fifth, it says nothing about microbial load. Vandeputte and colleagues showed that total microbial cell counts vary roughly tenfold between individuals, which means two people with identical stool form can be running fermentation at very different absolute rates (Nature, 2017).

What Stool Consistency Actually Tells Us About the Microbiome

The most important thing the Bristol Stool Scale does for microbiome science is act as a proxy for transit time, and transit time turns out to be one of the strongest single determinants of community structure.

Vandeputte and colleagues profiled the faecal microbiota of 53 healthy women against stool consistency and found that observed species richness correlated with consistency at r = -0.45 (p = 0.0007), with enterotype distribution and estimated bacterial growth rates also tracking consistency (Gut, 2016). Looser stool, meaning faster transit, was associated with lower richness. This is not a subtle effect; the authors concluded that stool consistency is a major confounder that microbiome studies must control for.

Roager and colleagues put the mechanism on firmer ground, showing that colonic transit time is related to bacterial metabolism and to mucosal turnover in the gut, with longer transit shifting metabolism from saccharolytic toward proteolytic as easily fermentable substrate is exhausted (Nature Microbiology, 2016). That is the biochemical explanation for why hard, slow-transit stool tends to carry more phenolic and indolic volatiles.

The most direct test came from Asnicar and colleagues, who measured transit time in 863 PREDICT 1 participants using a blue dye marker and compared it with the standard proxies. Measured transit time was more strongly associated with gut microbiome composition than either stool consistency or stool frequency, and longer transit was associated with species including Akkermansia muciniphila, Bacteroides and Alistipes (Gut, 2021). The Bristol Stool Scale is a usable proxy for transit. It is not the measurement itself.

What VOC Analysis Reveals Beneath the Surface

Volatile Organic Compounds and Metabolomic Profiling

When microbial cells ferment dietary substrates in the colon they produce hundreds of chemical compounds. Many are volatile, evaporating readily at body temperature. These are not merely waste; they are signaling molecules that interact with the immune system, the nervous system and metabolic regulation.

In the context of gut health assessment we measure short-chain fatty acids, secondary bile acid derivatives, phenolic compounds, indoles and dozens of other fermentation products. Colonic measurements by Cummings and colleagues put acetate, propionate and butyrate at roughly a 60:20:20 molar ratio, with total short-chain fatty acid concentrations in the region of 100 millimoles per litre in the proximal colon (Gut, 1987).

The reason this is powerful is that VOC analysis reports directly on what your microbiota is doing metabolically. Two individuals can share identical Bristol classifications and similar sequencing-based composition while showing completely different volatile profiles. Carrying a gene is not the same as expressing it.

The Biochemistry Behind Different Stool Types

The table below sets out what the transit and fermentation literature predicts for each Bristol category. The transit direction is established; the volatile signatures are the pattern the Roager and Garner work would predict rather than a validated per-type reference range.

Bristol type	Transit	Water content	Expected fermentation pattern	What it cannot tell you
Types 1-2	Slow	Low	Substrate exhausted; shift toward proteolytic metabolism, more phenolics and indoles	Whether the cause is low fiber, slow motility, or methanogenesis
Types 3-4	Within typical range	Moderate	Primary saccharolytic fermentation with the most robust short-chain fatty acid output	Whether butyrate output is actually adequate
Type 5	Slightly fast	Higher	Either healthy rapid fermentation or early dysbiosis; the two are visually identical	Which of the two it is, without a volatile profile
Types 6-7	Fast	High	Incomplete fermentation, primary fermentation products not fully converted	Whether the driver is bile acid malabsorption, infection, or dysbiosis

Type 5 is where things become clinically interesting. A Type 5 stool with elevated butyrate and propionate in a diverse, stable community suggests healthy function. A Type 5 stool with elevated volatile amines and reduced short-chain fatty acid production suggests something different. The Bristol Stool Scale cannot make this distinction. VOC analysis can.

The Missing Biomarkers

Research has associated specific volatile signatures with clinical outcomes across several conditions, and the numbers are now good enough to quote.

In inflammatory bowel disease, a 2024 systematic review and meta-analysis in the Journal of Crohn's and Colitis pooled 10 studies covering 696 cases against 605 controls and reported sensitivity 87 percent (95 percent CI 0.79 to 0.92), specificity 83 percent (95 percent CI 0.73 to 0.90) and an area under the curve of 0.92 (Krishnamoorthy et al., 2024). In colorectal cancer, Bond and colleagues analyzed fecal headspace from 137 participants and found that propan-2-ol combined with 3-methylbutanoic acid gave an AUROC of 0.82 with sensitivity 87.9 percent and specificity 84.6 percent (Alimentary Pharmacology & Therapeutics, 2019). In irritable bowel syndrome, Ahmed and colleagues identified fecal volatile organic metabolites that separated patients from controls, with the caveat that IBS is defined symptomatically rather than pathologically (PLoS ONE, 2013). Walton and colleagues showed the same approach distinguished chronic gastrointestinal disease states by bacterial-origin volatiles (Inflammatory Bowel Diseases, 2013), and Covington and colleagues applied a sensor-based tool specifically to bile acid diarrhoea (Sensors, 2013).

The direction of the evidence is consistent. The specific performance figures vary widely between studies and sampling protocols, and none of this yet constitutes a validated clinical test.

Integrating Visual and Molecular Assessment

Transit Time, Consistency and Fermentation

A comprehensive digestive health monitoring approach captures information across multiple timescales. The Bristol Stool Scale contributes an instantaneous snapshot of water content and consistency. VOC analysis contributes the current metabolic output of the microbial ecosystem.

The Bristol Stool Scale averages transit across a single defecation event. It does not capture variability or temporal dynamics. Someone could show Type 5 consistency every day while their underlying fermentation pattern drifts, and snapshot observation would miss it entirely. For the broader scientific framework here, see our overview of gut microbiome science and VOC analysis.

Short-Chain Fatty Acids and Metabolic Health

Short-chain fatty acids deserve particular attention because they are among the most significant and least appreciated messengers produced by gut microbiome communities. Acetate, propionate and butyrate are produced when microbial cells ferment dietary fiber and resistant starch, and they contribute a meaningful share of daily colonic energy supply rather than being minor metabolites.

Butyrate warrants extended discussion. It serves as the preferred energy source for colonocytes. Beyond that, it acts as a histone deacetylase inhibitor, influencing which genes intestinal epithelial cells express, and research associates it with strengthened barrier function, reduced inflammation and development of regulatory T cells (Parada Venegas et al., Frontiers in Immunology, 2019; Mann et al., Nature Reviews Immunology, 2024). Its principal producer, Faecalibacterium prausnitzii, is depleted in Crohn's disease, and both the organism and its culture supernatant reduced inflammation in experimental colitis (Sokol et al., PNAS, 2008).

The Bristol Stool Scale tells you nothing about your butyrate production. You could have Type 3 consistency, ostensibly normal, alongside low butyrate output. You could have Type 5 consistency alongside robust butyrate production. Appearance is decoupled from metabolic reality.

Hypothetical scenario. As an illustrative scenario, imagine someone increasing fermentable fiber from roughly 15 grams to roughly 30 grams a day over four weeks. Their Bristol classification stays at Type 4 throughout. Based on the mechanisms Roager and colleagues describe, the volatile profile would be expected to shift toward short-chain fatty acid derived compounds and away from phenolics and indoles, because more substrate is reaching the distal colon. On stool form alone the intervention looks like it did nothing. This is a constructed illustration of published mechanism, not a real person and not a SNIFR result.

Standardization and Clinical Validation

Methodological Realities

It is worth being honest about where this technology stands, because exciting research and ready for widespread clinical use are not synonymous. Gas chromatography-mass spectrometry remains the reference method for VOC measurement, offering excellent sensitivity, specificity and quantitation, but it requires expensive equipment, trained operators and sophisticated data processing. More accessible platforms including electronic nose technologies and portable spectrometry involve trade-offs in specificity or quantitative accuracy.

Sample handling matters enormously. Temperature exposure degrades volatile compounds. Oxidation occurs. Bacterial activity during storage alters fermentation products. Time between collection and analysis is critical. This is precisely why at-home monitoring platforms must emphasize controlled collection, optimized preservation and research-grade analytical methodology.

What Clinical Validation Requires

Clinical validation means controlled studies comparing measurements against established biomarkers, demonstrating that they predict clinically relevant outcomes, showing reproducibility across populations, and publishing results in peer-reviewed venues.

The 2024 work of Zheng and colleagues shows what a completed version looks like in an adjacent modality: 5,979 fecal metagenomes across multiple geographies and ethnicities, ten-species and nine-species models for ulcerative colitis and Crohn's disease reaching areas under the curve above 0.90 in discovery, held across trans-ethnic validation cohorts from eight populations, then converted into a droplet digital PCR assay practical for clinical laboratories (Nature Medicine, 2024). Fecal VOC analysis has not yet completed that sequence. Evidence-based does not mean proven infallible. It means studied systematically, compared against established standards, published in peer-reviewed venues, and honest about limitations.

Practical Application Across Clinical Scenarios

IBS-D and Diarrhea Patterns

Consider someone with IBS-D, the diarrhea-predominant subtype of irritable bowel syndrome. Irritable bowel syndrome as a whole, not the diarrhea-predominant subtype alone, has a pooled global prevalence of about 11.2 percent (95 percent CI 9.8 to 12.8) in a meta-analysis of 80 studies covering more than 260,000 people (Lovell and Ford, Clinical Gastroenterology and Hepatology, 2012). Clinically, someone with IBS-D is likely experiencing Type 6 or Type 7 stools consistently, along with visceral pain and urgency.

The Bristol Stool Scale confirms the consistency problem but says nothing about cause. The underlying mechanisms could involve accelerated transit, dysbiosis producing gas and bloating, an infectious trigger, bile acid malabsorption, or food sensitivity. Each implies a different approach.

Volatile profiling can help distinguish between these patterns. Covington and colleagues showed that a sensor-based volatile analysis could identify bile acid diarrhoea specifically, which is a clinically actionable distinction because it has a specific treatment (Sensors, 2013). A profile dominated by proteolytic fermentation products points elsewhere. Each pattern suggests different avenues, which is information the visual scale cannot supply.

Monitoring Inflammatory Conditions

In inflammatory bowel disease, standard monitoring includes endoscopy, inflammatory biomarkers and symptom assessment. The Bristol Stool Scale is particularly crude here, since Type 7 diarrhea and bloody diarrhea look similar on the scale while carrying very different implications.

What research shows is that butyrate-producing bacteria are typically depleted in inflammatory bowel disease, and that fecal volatile profiles separate patients from controls with pooled sensitivity 87 percent and specificity 83 percent across the studies meta-analyzed to date. The hypothesis that longitudinal volatile monitoring could detect dysbiotic shifts before clinical deterioration is genuinely interesting, but it remains a hypothesis under investigation rather than a demonstrated capability.

Tracking Dietary Interventions

Finally, consider someone transitioning to a higher-fiber diet or reducing processed foods. The Bristol Stool Scale might show no change: Type 4 before, Type 4 after. Did the intervention work?

Volatile profiling can answer this. If the profile shifts toward higher butyrate and propionate, lower variance across samples, and more stable fermentation patterns, the intervention is working at the metabolic level even when visible consistency has not changed.

The Future of Comprehensive Stool Assessment

The direction of the field is toward integrated platforms combining multiple measurement modalities from a single collection: Bristol classification, metabolomic analysis through volatile compound assessment, compositional sequencing, and machine learning interpretation. The component technologies exist; the integration is what is being built.

The real power emerges with temporal dynamics. A single volatile profile describes a moment. A year of profiles describes a trajectory. Whether continuous monitoring can support flare-up prediction as a genuine early warning system is exactly the question the field needs to answer, and it is the design goal behind SNIFR's at-home monitoring work rather than a proven capability.

From Assessment to Action

A practical workflow based on current evidence-based approaches looks roughly like this:

• Start with the accessible. Keep a brief Bristol Stool Scale log covering consistency, frequency and associated symptoms. It requires no equipment and produces clear patterns within a week or two. Remember that form correlates with transit at around r = -0.54, so treat it as a signal rather than a measurement.
• Add molecular measurement. A single sample provides a snapshot; multiple samples over weeks provide a trajectory.
• Interpret the two together. A Type 5 stool with high butyrate means something different from a Type 5 stool with low butyrate.
• Implement and monitor. Judge an intervention by whether it produces favorable changes in the volatile profile, not only by whether stool form changes.

Honest Caveats

These technologies cannot diagnose disease. They produce data that can inform decision-making, but they do not replace medical evaluation. Anyone with chronic diarrhea needs proper assessment to rule out infectious, inflammatory and structural causes, and no amount of at-home monitoring substitutes for that.

Standardized interpretation frameworks are also still developing. A finding of low butyrate is interpretable. Which specific dietary changes will raise butyrate production in your particular microbiota is a harder question that current standardized approaches answer only partially. And more data is not automatically better data; without good interpretive frameworks, volume can impair rather than improve judgment.

What is defensible is this: integrating classical clinical assessment with modern molecular measurement provides a substantially better understanding of digestive health than either approach alone. The gap between what we see and what is actually happening in the colon is shrinking, and that is genuine progress.

Frequently Asked Questions

What does the Bristol Stool Scale actually measure?

The Bristol Stool Scale measures one variable: stool consistency, which mostly reflects colonic transit time and water content. In the original 1997 validation across 66 volunteers, stool form correlated with whole-gut transit time at r = -0.54, better than either defecation frequency or stool output. It is a useful shared language, but it describes appearance rather than biochemistry.

How accurate is the Bristol Stool Scale?

Blake and colleagues tested 169 healthy adults against measured stool water content and had 86 volunteers classify 26 standardized stool models. They reported substantial overall validity and reliability, but found that accuracy degraded specifically at the boundaries between Types 2 and 3 and between Types 5 and 6, which are the boundaries that matter most clinically.

Can two people have the same Bristol type but different gut health?

Yes, and this is the central limitation of visual assessment. A Type 5 stool can accompany healthy fermentation with strong short-chain fatty acid production, or early dysbiosis with elevated volatile amines and low butyrate. Total microbial load also varies roughly tenfold between people, so identical appearance can mean very different absolute fermentation rates.

Does stool consistency really affect microbiome results?

Substantially. Vandeputte and colleagues found that species richness correlated with stool consistency at r = -0.45 in 53 healthy women, with enterotype and bacterial growth rates also tracking consistency. Looser stool, meaning faster transit, was associated with lower richness. Microbiome studies now routinely treat stool consistency as a confounder that must be controlled for.

How does VOC analysis add to the Bristol Stool Scale?

VOC analysis measures what your microbiota is doing metabolically, while the Bristol Stool Scale describes what the result looks like. Garner and colleagues identified 297 volatile compounds in fecal headspace, and pooled VOC performance in inflammatory bowel disease reaches sensitivity 87 percent and specificity 83 percent. Neither approach replaces the other.

How should someone with IBS-D use stool tracking?

Keeping a simple Bristol log alongside symptoms and diet builds useful context within a week or two, since IBS-D typically presents as consistent Type 6 or Type 7 stools. Adding molecular measurement can help distinguish underlying patterns that look identical on the scale, including bile acid diarrhoea, which has a specific treatment. Any persistent change in bowel habit warrants medical evaluation.

Why might a dietary change not show up on the Bristol Stool Scale?

Consistency is a coarse measure, so a meaningful shift in bacterial metabolism can occur while stool form stays the same. Colonic transit time governs whether metabolism runs saccharolytic or proteolytic, and that can shift well before water content does. Without molecular measurement, an intervention that is working can look like it is doing nothing.

References

• Lewis SJ, Heaton KW. Stool Form Scale as a Useful Guide to Intestinal Transit Time. Scandinavian Journal of Gastroenterology. 1997;32(9):920-924. doi:10.3109/00365529709011203
• Saad RJ, Rao SS, Koch KL, et al. Do Stool Form and Frequency Correlate With Whole-Gut and Colonic Transit? Results From a Multicenter Study in Constipated Individuals and Healthy Controls. American Journal of Gastroenterology. 2010;105(2):403-411. doi:10.1038/ajg.2009.612
• Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2016;44(7):693-703. doi:10.1111/apt.13746
• Vandeputte D, Falony G, Vieira-Silva S, et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65(1):57-62. doi:10.1136/gutjnl-2015-309618
• Roager HM, Hansen LBS, Bahl MI, et al. Colonic transit time is related to bacterial metabolism and mucosal turnover in the gut. Nature Microbiology. 2016;1(9):16093. doi:10.1038/nmicrobiol.2016.93
• Asnicar F, Leeming ER, Dimidi E, et al. Blue poo: impact of gut transit time on the gut microbiome using a novel marker. Gut. 2021;70(9):1665-1674. doi:10.1136/gutjnl-2020-323877
• Vandeputte D, Kathagen G, D'hoe K, et al. Quantitative microbiome profiling links gut community variation to microbial load. Nature. 2017;551(7681):507-511. doi:10.1038/nature24460
• Lovell RM, Ford AC. Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. Clinical Gastroenterology and Hepatology. 2012;10(7):712-721.e4. doi:10.1016/j.cgh.2012.02.029
• Garner CE, Smith S, de Lacy Costello B, et al. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. The FASEB Journal. 2007;21(8):1675-1688. doi:10.1096/fj.06-6927com
• Ahmed I, Greenwood R, de Lacy Costello B, et al. An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PLoS ONE. 2013;8(3):e58204. doi:10.1371/journal.pone.0058204
• Walton C, Fowler DP, Turner C, et al. Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases. Inflammatory Bowel Diseases. 2013;19(10):2069-2078. doi:10.1097/MIB.0b013e31829a91f6
• Bond A, Greenwood R, Lewis S, et al. Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer. Alimentary Pharmacology & Therapeutics. 2019;49(8):1005-1012. doi:10.1111/apt.15140
• Krishnamoorthy A, Chandrapalan S, Ahmed M, et al. The diagnostic utility of volatile organic compounds in inflammatory bowel disease: a systematic review and meta-analysis. Journal of Crohn's and Colitis. 2024;18(2):320-330. doi:10.1093/ecco-jcc/jjad132
• Covington JA, Westenbrink EW, Ouaret N, et al. Application of a novel tool for diagnosing bile acid diarrhoea. Sensors. 2013;13(9):11899-11912. doi:10.3390/s130911899
• Cummings JH, Pomare EW, Branch WJ, et al. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28(10):1221-1227. doi:10.1136/gut.28.10.1221
• Parada Venegas D, De la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Frontiers in Immunology. 2019;10:277. doi:10.3389/fimmu.2019.00277
• Mann ER, Lam YK, Uhlig HH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nature Reviews Immunology. 2024;24(8):577-595. doi:10.1038/s41577-024-01014-8
• Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences. 2008;105(43):16731-16736. doi:10.1073/pnas.0804812105
• Zheng J, Sun Q, Zhang M, et al. Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. Nature Medicine. 2024;30(12):3555-3567. doi:10.1038/s41591-024-03280-4
• Dalis C, Mesfin FM, Manohar K, et al. Volatile Organic Compound Assessment as a Screening Tool for Early Detection of Gastrointestinal Diseases. Microorganisms. 2023;11(7):1822. doi:10.3390/microorganisms11071822

SNIFR is designed to provide insights about gut health patterns, not to diagnose or treat medical conditions. Individual results may vary as gut health is influenced by numerous factors including diet, stress, sleep, and genetics. SNIFR is currently in development, and features described may evolve before commercial release.